NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $18.05 +0.12 (+0.67%) (As of 11:20 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Entrada Therapeutics Stock (NASDAQ:TRDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$17.60▼$18.1050-Day Range$13.65▼$19.9652-Week Range$10.75▼$20.49Volume24,206 shsAverage Volume106,846 shsMarket Capitalization$675.43 millionP/E Ratio11.35Dividend YieldN/APrice Target$24.00Consensus RatingBuy Company OverviewEntrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Entrada Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 708th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.07 to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is 11.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is 11.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.28.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.68% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.68% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing. News and Social Media0.9 / 5News SentimentN/A News SentimentEntrada Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $410,816.00 in company stock.Percentage Held by InsidersOnly 7.59% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Stock News HeadlinesNatarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockNovember 14, 2024 | insidertrades.comEntrada Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 7, 2024 | finance.yahoo.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 21, 2024 | Crypto 101 Media (Ad)Entrada Therapeutics: Strong Buy Recommendation Backed by Promising Clinical Progress and Robust Financial HealthNovember 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)November 7, 2024 | markets.businessinsider.comEntrada Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | markets.businessinsider.comHere's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price StrengthOctober 15, 2024 | finance.yahoo.comEntrada Therapeutics (NASDAQ:TRDA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA stock has increased by 19.0% and is now trading at $17.95. View the best growth stocks for 2024 here. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) posted its quarterly earnings results on Tuesday, August, 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.90. The company earned $94.69 million during the quarter, compared to analyst estimates of $55 million. Entrada Therapeutics had a trailing twelve-month return on equity of 16.11% and a net margin of 25.53%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' top institutional shareholders include FMR LLC (4.66%), Janus Henderson Group PLC (4.57%), Wellington Management Group LLP (2.75%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim, Nerissa Kreher and John F Crowley. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/13/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$28.00 Low Stock Price Target$20.00 Potential Upside/Downside+33.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.59 Trailing P/E Ratio11.29 Forward P/E Ratio16.78 P/E GrowthN/ANet Income$-6,680,000.00 Net Margins25.53% Pretax Margin35.51% Return on Equity16.11% Return on Assets10.39% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$129.01 million Price / Sales5.21 Cash FlowN/A Price / Cash FlowN/A Book Value$11.29 per share Price / Book1.59Miscellaneous Outstanding Shares37,420,000Free Float34,580,000Market Cap$671.69 million OptionableOptionable Beta-0.26 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TRDA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.